33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients (pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product
    Meeting Abstract

    Jacobson, C. A.; Locke, F. L.; Miklos, D. B.; Vose, J. M.; Lin, Y.; Budde, L. E.; Maloney, D. G.; Jaglowski, S.; Riedell, P. A.; Lekakis, L. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Expert curation of somatic variants in hematological malignancies by the ClinGen Somatic Hematological Cancer Taskforce (ClinGen HCT)
    Meeting Abstract

    Kanagal-Shamanna, R.; Rao, S.; Terraf, P.; Raca, G.; Saliba, J.; Danos, A.; Mani, C.; Williams, H.; Jiang, N.; Vavra, K. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • ZRSR2 mutation induced minor intron retention drives MDS and diverse cancer predisposition via aberrant splicing of LZTR1
    Meeting Abstract

    Inoue, D.; Polaski, J. T.; Taylor, J.; Castel, P.; Chen, S.; Kobayashi, S.; Hogg, S. J.; Hayashi, Y.; Pineda, J. M. B.; Penson, A. V.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Co-targeting BET bromodomain proteins and aberrant signaling in AML
    Meeting Abstract

    Huang, B. J.; Wang, X.; Harris, M.; Wandler, A.; Hwang, E.; Burgess, M. R.; Li, Q.; Severson, P.; Powell, B.; Kolb, E. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Horwitz, S. M.; Foran, J. M.; Maris, M.; Sawas, A.; Okada, C.; Feldman, T. A.; Minden, M. D.; Sokol, L.; Mei, M.; Flinn, I. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The role of (18)F-FDG-PET/CT in characterizing depth of response in high risk smoldering multiple myeloma patients treated with carfilzomib, lenalidomide, and dexamethasone (KRd)
    Meeting Abstract

    Hill, E.; Korde, N.; Morrison, C.; Dew, A.; Carpenter, A.; Epstein, M.; Lu, C.; Choyke, P.; Mena, E.; Lindenberg, L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase Ib trial with dose expansion of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent primary central nervous system lymphoma (PCNSL) and refractory/recurrent secondary central nervous system lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Piotrowski, A.; Pentsova, E.; Nolan, C.; Francis, J.; DeAngelis, L.; Schaff, L.; Mellinghoff, I. K.
    Blood (2020)

    Fulltext@MSK | Save
  • Frequency and prognostic significance of recurrent gene mutations in pediatric B-ALL: Report from the DFCI ALL Consortium
    Meeting Abstract

    Gotti, G.; Puligandla, M.; Stevenson, K. E.; Mar, B. G.; Asselin, B. L.; Athale, U.; Clavell, L. A.; Cole, P. D.; Gennarini, L. M.; Kahn, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save